tbuckley/cabot-search huggingface dataset:
Relationship Between Steroid Excretion Patterns and Breast Cancer Incidence in Israeli Women of Various Origins2
Authors: J. Gross, B. Modan, B. Bertini, O. Spira, F. de Waard, J.H.H. Thijssen, P. Vestergaard
Journal: JNCI Journal of the National Cancer Institute (1977)

Journal Article Relationship Between Steroid Excretion Patterns and Breast Cancer Incidence in Israeli Women of Various Origins Get access J. Gross, M.D., J. Gross, M.D. Search for other works by this author on: Oxford Academic PubMed Google Scholar B. Modan, M.D., B. Modan, M.D. Search for other works by this author on: Oxford Academic PubMed Google Scholar B. Bertini, M.D., B. Bertini, M.D. Search for other works by this author on: Oxford Academic PubMed Google Scholar O. Spira, Ph.D., O. Spira, Ph.D. Search for other works by this author on: Oxford Academic PubMed Google Scholar F. de Waard, M.D., F. de Waard, M.D. Search for other works by this author on: Oxford Academic PubMed Google Scholar J.H.H. Thijssen, Ph.D., J.H.H. Thijssen, Ph.D. Search for other works by this author on: Oxford Academic PubMed Google Scholar P. Vestergaard, Ph.D. P. Vestergaard, Ph.D. Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 59, Issue 1, July 1977, Pages 7–11, https://doi.org/10.1093/jnci/59.1.7 Published: 01 July 1977 Article history Received: 20 May 1976 Revision received: 27 December 1976 Accepted: 05 January 1977 Published: 01 July 1977
The Extent of Serum Periostin Reduction in Asthma Patients Treated with Lebrikizumab Is Related to Baseline Periostin Levels: A Pooled Analysis of Phase II Studies
Authors: David F. Choy, Cecile T.J. Holweg, Fang Cai, Joseph R. Arron, John G. Matthews, Heleen Scheerens
Journal: Journal of Allergy and Clinical Immunology (2016)
P0890 : Novel cyclophilin inhibitor CPI-431-32 shows broad spectrum antiviral activity by blocking replication of HCV, HBV and HIV-1 viruses
Authors: P. Gallay, U. Chatterji, M. Bobardt, D. Ure, D. Trepanier, R. Foster, C. Ordonez
Journal: Journal of Hepatology (2015)
Variable Contribution of Heart Failure to Quality of Life in Ambulatory Heart Failure With Reduced, Better, or Preserved Ejection Fraction
Authors: Emer Joyce, Christine Chung, Sabrina Badloe, Kayode Odutayo, Akshay Desai, Michael M Givertz, Anju Nohria, Neal K Lakdawala, Garrick C Stewart, Michelle Young, Joanne Weintraub, Lynne W Stevenson, Eldrin F Lewis
Journal: JACC Heart Failure (2016)
The effect of increasing the dose of hydroxychloroquine (HCQ) in patients with refractory cutaneous lupus erythematosus (CLE): An open-label prospective pilot study
Authors: François Chasset, Laurent Arnaud, Nathalie Costedoat-Chalumeau, Noel Zahr, Didier Bessis, Camille Francès
Journal: Journal of the American Academy of Dermatology (2016)
Mesenchymal stem cells selectively engraft into tumor stroma and produce potent antitumor proteins <i>in situ</i>
Authors: M. Andreeff, J. Dembinski, M. Studeny, X. Ling, T. McQueen, A. Klopp, F. Marini
Journal: Journal of Clinical Oncology (2007)

3025 Background: The formation of stroma is essential for tumor growth and involves complex interactions between malignant cells and non-tumor stromal cells. We have previously demonstrated that IV injected bone marrow derived mesenchymal stem cells (MSC) integrate into solid tumors as stromal elements (Cancer Res 62:3603, 2002; JNCI 96:1593, 2004). Methods: MSC were labeled by a fiber modified Ad vector expressing firefly luciferase (AdLux-F/RGD), injected into normal or tumor-bearing SCID mice, and biodistributed MSC-Lux were imaged utilizing the Xenogen IVIS system. Results: After IP injection, no hMSC-LUX were detected in normal animals after 7 days, while strong punctate regions of LUX-activity were observed in ovarian tumors. Tumor cells transduced with renilla luciferase constructs co- localized with firefly luciferase MSC. Next, we examined whether hMSC-producing interferon-beta (IFNβ-MSC) could inhibit the growth of metastatic tumors in the lungs of SCID mice. When injected IV (4 doses of 10 6 MSC/week) into SCID mice with pulmonary metastases of carcinomas or melanomas, tumor growth was significantly inhibited as compared with untreated or vector-control MSC controls (p= 0.007). IV injected IFNb-MSC prolonged the survival of mice bearing metastatic breast carcinomas (p=0.001). In an orthotopic, chemoresistant breast cancer model in syngeneic immunocompetent mice, MSC producing IFN-β completely abrograted tumor growth. Localized low-dose XRT to tumors significantly increased the number of tumor-resident MSC. Conclusions: The data suggest that systemically administered gene-modified MSC selectively engraft into the tumor microenvironment and remain resident as part of the tumor architecture. MSC-expressing IFN-β inhibit the growth of melanomas, gliomas, metastatic breast and ovarian cancers in vivo and prolong the survival of mice bearing established tumors. Clinical trials are in preparation. No significant financial relationships to disclose.
Have splenectomy rate and main outcomes of ITP changed after the introduction of new treatments? A monocentric study in the outpatient setting during 35 years
Authors: Francesca Palandri, Nicola Polverelli, Daria Sollazzo, Marco Romano, Lucia Catani, Michele Cavo, Nicola Vianelli
Journal: American Journal of Hematology (2016)

In the last years, rituximab (RTX) and agonists of the thrombopoietin receptor (TPO‐R) eltrombopag and romiplostim have provided new treatment options in persistent and chronic immune thrombocytopenia (ITP). Here, we analyzed the changes in therapeutic choices over time and their impact on clinical outcomes in a cohort of 557 ITP outpatients followed at the “L. and A. Seràgnoli” Institute of Hematology, Bologna, Italy, from 1980 to 2015. Overall 397 patients (71%) required front‐line corticosteroids, mainly prednisone. Over the decades, splenectomy was delayed from second to third‐line, but was steadily used in around 15–25% of patients refractory or relapsing after first‐line treatment. Consensually, RTX and TPO‐R agonists emerged as second and third‐line therapy of choice, respectively. Splenectomy was associated with the best response rates and the lower incidences of relapse, while the relapse rate after RTX was comparable to that observed with corticosteroids and other immunosuppressive agents. The introduction of TPO‐R agonists gave an alternative to the administration of immunosuppressive drugs and probably contributed to moderate the incidence of infectious complications that remained stable over the decades, despite an increasing use of RTX from the 2000s onwards. Overall responses were similar over time, with over 97% achieving a response in all time‐periods. However, the cumulative risk of bleeding significantly decreased [14.3% (1980–89) vs. 7% (1990–99) vs. 5.6% (2000–09) vs. 0.2% (2010–15)] ( P &lt; 0.001), mainly thanks to the optimization of front‐line corticosteroids therapy and to the wider availability of second and third‐line therapies. Am. J. Hematol. 91:E267–E272, 2016. © 2016 Wiley Periodicals, Inc.
Abstract 16604: A Novel Endocardial Activation Analysis Software to Identify Rapid Activation Patterns During Atrial Fibrillation
Authors: Raul Weiss, Ziad Zeidan, John D Hummel, Steven J Kalbfleisch, Ralph Augostini, Mahmoud Houmsse, Emile G Daoud
Journal: Circulation (2014)

Introduction: The cornerstone of atrial fibrillation (AF) radiofrequency ablation (RFA) is pulmonary vein (PV) isolation. A recently described technique directs RFA to electrical rotors identified by computational analyses of 64-electrode basket catheter (BC) endocardial recordings of AF. Hypothesis: The purpose of this study was to develop and then to assess the ability of a novel analysis method, CartoFinder™ (CF), incorporated into a 3D mapping system, CARTO (Biosense Webster, CA, USA) to identify rapid activation patterns (RAP). Methods: 20 patients who were undergoing RFA AF utilizing CARTO mapping and who consented were enrolled. 1 minute BC maps of the right (RA) and left (LA) were obtained after creation of a 3D virtual anatomic shell prior to and after RFA around the PV. In each atria, 2 BC recordings were obtained at the same location, separated by 5 minutes. Results: Unipolar signals from the BC were recorded by CARTO and analyzed offline. The signal was processed to filter out far-field ventricular activity and the remaining signals were analyzed to create dynamic 3D activation maps and visually identify RAP. CF labels the leading edge of activation with a red color. Of these 20 patients, CF recordings were complete in 14 pts (mean age 59; 12 with persistent AF). There were 2.8 RAP / pt. (mean 1.3 RA; 1.6 LA). No RAP were recorded in 2 pts. The correlation of the BC separated by 5 minutes to identify the same RAP was 12/15 in RA and 15/18 in LA (total: 27/33, 82%). Conclusions: CF is a newly developed online technique to identify RAP incorporated into a conventional 3D mapping system. RAPs can be identified in the majority of patients undergoing RFA AF with approximately 80% reproducibility.
What's new in IL-12? Combination!
Authors: Chris E Lawrence, Mark Rubinstein, Zoya Gluzman-Poltorak, Vladimir Vainstein, Lena A Basile
Journal: Journal for ImmunoTherapy of Cancer (2015)

Meeting abstracts IL-12 is a heterodimeric, pro-inflammatory cytokine that enhances the cytotoxic activity of natural killer (NK) cells and cytotoxic CD8+ T-lymphocytes, and induces an IFN-α-dominated Th1 CD4+ T-lymphocyte response. IL-12 as an immunotherapeutic agent administered subcutaneously
Allogeneic Hematopoietic Stem Cell Transplantation From Haploidentical Donor After Reduced Intensity Conditioning Regimen Allows Promising Disease Control In Patients With Hematological Diseases
Authors: Raynier Devillier, Luca Castagna, Roberto Crocchiolo, Sabine Furst, Samia Harbi, Jean El Cheikh, Angela Granata, Bilal Mohty, Catherine Faucher, Didier Blaise
Journal: Blood (2013)
Physicians' Awareness and Understanding of Personalized Medicine in the Treatment of Cancer and Its Adoption in Clinical Practice: a Multinational Survey
Authors: F. Ciardiello, J. Tabernero, T. Seufferlein, J. Taïeb, V. Moiseyenko, B. Ma, G. López, R. Esser, R. Adams
Journal: Annals of Oncology (2014)
A phase II study of paclitaxel in chemonaïve patients with recurrent high-grade glioma
Authors: T.J. Postma, J.J. Heimans, S.A. Luykx, C.J. van Groeningen, L.F.M. Beenen, O.S. Hoekstra, M.J.B. Taphoorn, B.A. Zonnenberg, M. Klein, J.B. Vermorken
Journal: Annals of Oncology (2000)
Preservation of Antegrade Ejaculation in Retroperitoneal Lymphadenectomy due to Residual Masses after Primary Chemotherapy for Testicular Carcinoma
Authors: E. Solsona, I. Iborra, J.V. Ricós, J.L. Monrós, R. Dumont, J. Casanova, V. Guillem
Journal: European Urology (1994)
Excess of other cancers in Wales
Authors: C Busby
Journal: BMJ (1994)

Prostatic cancer and radionuclidesEvidence implicates zinc-65EDrroR,-In their paper on prostatic cancer in employees of the United Kingdom Atomic Energy Authority, Cleone Rooney and colleagues raise the possibility of localisation of zinc-65 in the prostate being an aetiological factor but state that "there are no reliable data on 65Zn uptake by the human prostate."'Prout et al showed in 1959 that 65Zn localises avidly in the prostate in human males, and especially in benign adenomas.2In 1956 Daniel et al showed that the ratio of the 65Zn concentration in normal prostates to that in blood was over 2-5:1; one patient had a ratio of 27:1.3The consensus of both groups was that neoplastic prostates concentrated less zinc.The uptake of zinc by the human prostate is so high that it is technically possible to image the prostate with ""9Zn."(Unfortunately, there are no isotopes of zinc suitable for routine imaging, so this approach has not found a place in routine nuclear medicine.)This avid uptake of zinc by the prostate must increase the probability of 65Zn being a relevant factor in carcinogenesis in this population.
Cryoglobulinemia after Hepatitis B Vaccination
Authors: Emmanuel Mathieu, Olivier Fain, Alain Krivitzky
Journal: New England Journal of Medicine (1996)

To the Editor: Vaccination with hepatitis B recombinant vaccine has few serious side effects1 (about 1 per 100,000 doses administered). Some cases of vasculitis have been reported.2 We report two c...
Epithelial–Mesenchymal Transition Is Associated with a Distinct Tumor Microenvironment Including Elevation of Inflammatory Signals and Multiple Immune Checkpoints in Lung Adenocarcinoma
Authors: Yanyan Lou, Lixia Diao, Edwin Roger Parra Cuentas, Warren L. Denning, Limo Chen, You Hong Fan, Lauren A. Byers, Jing Wang, Vassiliki A. Papadimitrakopoulou, Carmen Behrens, Jaime Canales Rodriguez, Patrick Hwu, Ignacio I. Wistuba, John V. Heymach, Don L. Gibbons
Journal: Clinical Cancer Research (2016)

Abstract Purpose: Promising results in the treatment of non–small cell lung cancer (NSCLC) have been seen with agents targeting immune checkpoints, such as programmed cell death 1 (PD-1) or programmed death ligand-1 (PD-L1). However, only a select group of patients respond to these interventions. The identification of biomarkers that predict clinical benefit to immune checkpoint blockade is critical to successful clinical translation of these agents. Methods: We conducted an integrated analysis of three independent large datasets, including The Cancer Genome Atlas of lung adenocarcinoma and two datasets from MD Anderson Cancer Center (Houston, TX), Profiling of Resistance Patterns and Oncogenic Signaling Pathways in Evaluation of Cancers of the Thorax (named PROSPECT) and Biomarker-Integrated Approaches of Targeted Therapy for Lung Cancer Elimination (named BATTLE-1). Comprehensive analysis of mRNA gene expression, reverse-phase protein array, IHC, and correlation with clinical data were performed. Results: Epithelial–mesenchymal transition (EMT) is highly associated with an inflammatory tumor microenvironment in lung adenocarcinoma, independent of tumor mutational burden. We found immune activation coexistent with elevation of multiple targetable immune checkpoint molecules, including PD-L1, PD-L2, PD-1, TIM-3, B7-H3, BTLA, and CTLA-4, along with increases in tumor infiltration by CD4+Foxp3+ regulatory T cells in lung adenocarcinomas that displayed an EMT phenotype. Furthermore, we identify B7-H3 as a prognostic marker for NSCLC. Conclusions: The strong association between EMT status and an inflammatory tumor microenvironment with elevation of multiple targetable immune checkpoint molecules warrants further investigation of using EMT as a predictive biomarker for immune checkpoint blockade agents and other immunotherapies in NSCLC and possibly a broad range of other cancers. Clin Cancer Res; 22(14); 3630–42. ©2016 AACR. See related commentary by Datar and Schalper, p. 3422
A clinicopathological study of Epstein-Barr virus positive (EBV+) smooth muscle tumours (SMT) in adult renal transplant recipients
Authors: H. C. Toh, K. W. Ong, V. K. N. Lee, A. S. Lee, M. Teo, E. Chan, A. Vathsala
Journal: Journal of Clinical Oncology (2005)

9064 Background: EBV+ SMT is a rare tumour in immunocompromised individuals. We present the clinicopathological characteristics of EBV+ SMT in 8 adult renal allograft recipients in arguably the largest reported single series. Methods: From the SGH renal transplant registry from 1989 to 2004, 8 EBV+ SMT cases and their histopathology were re-evaluated for diagnostic confirmation. Results: The total number of renal transplant patients in this 15 year period was 667 with 88 patients diagnosed with cancer. EBV+ SMT was higher in incidence (7.4%) than post-transplant lymphoproliferative disease (PTLD) (5.6%). Five patients were male, 3 female, all were Chinese, with a median age of 42 years (29 - 61 years). Median time-to-EBV+SMT diagnosis from renal transplant was 6 years. Four patients were symptomatic at diagnosis and 6 had multiple sites of tumour at presentation including larynx, pharynx, duodenum, lung, breast, liver, spleen, bladder, bone, kidney and adrenal glands. Four are alive with a median survival of 41 months, but no deaths were EBV+SMT-related. The EBV+SMT were indolent in behaviour and tapering of immunosuppression for all patients yielded no objective responses. One patient with biopsy-proven multiple EBV+SMT liver nodules that progressed on immunosuppression taper was treated with rapamycin with durable complete radiological regression. The morphological features of all 8 patient tumour specimens show smooth muscle differentiation. EBV encoded RNA in-situ hybridisation (EBER-ISH) and Epstein-Barr Nuclear Antigen-2 (EBNA-2) were positive in all patients. By IHC, smooth muscle actin (SMA) was strongly positive in all patients and desmin-positive in 6 patients. Immunohistochemistry staining in all 8 patients was negative for CD21, bcl-2 and weakly detectable for Ki-67. Conclusion: The comparably high incidence of EBV+SMT in immunosuppresed patients with a Chinese predominance suggests there may be an ethnic/geographical predisposition such as with nasopharyngeal cancer. Rapamycin may be a potential therapy for EBV+SMT. No significant financial relationships to disclose.
The limits of neurophysiological models of consciousness
Authors: Max Velmans
Journal: Behavioral and Brain Sciences (1995)

Abstract This commentary elaborates on Gray's conclusion that his neurophysiological model of consciousness might explain how consciousness arises from the brain, but does not address how consciousness evolved, affects behaviour or confers survival value. The commentary argues that such limitations apply to all neurophysiological or other thirdperson perspective models. To approach such questions the first-person nature of consciousness needs to be taken seriously in combination with third-person models of the brain.
Phase I study of capecitabine (C) in combination with cisplatin (DDP) and irinotecan (IRI) in patients (pts) with advanced solid malignancies
Authors: H. Sayar, C. F. Verschraegen, H. Smith, I. Rabinowitz, F. C. Lee, Z. Shen
Journal: Journal of Clinical Oncology (2008)

13515 Background: This phase I trial in pts with advanced solid malignancies assessed the safety and the maximum tolerated dose (MTD) of C given for 10 days prior to a combination of DDP and IRI. It is hypothesized that C will promote DNA adducts of DDP with IRI. Methods: Pts with advanced solid tumors who were considered incurable and had not failed 5-Fluorouracil (5-FU) analogs or topoisomerase I inhibitors were eligible. Serial cohorts of pts (3+3 Phase I design) received one cycle (internal control) of DDP (50 mg/m2) on Day 1 and IRI (50 mg/m2) on Days 1, 8, and 15. Starting after 1 wk of rest, C was administered from Days 1 to 10, at increasing doses/cohort, followed by a second cycle of DDP/IRI which started on Day 11. The starting dose of C was 500 mg/m2/day and escalated in subsequent cohorts by 250 mg/m2/day until MTD. Three additional patients were treated at the recommended phase II dose to further evaluate the safety, adducts, and tumor response. Patient mononuclear cells were tested for DNA DDP adducts at various time points (prior to Days 1 and 8 on the first cycle, prior to Days 1, 11, 18, and 32 on the second cycle). Results: Fifteen patients received at least 2 cycles of treatment. The MTD for C was determined to be 1250 mg/m2/day with excessive grade 4 neutropenia, and the recommended dose is thus 1000 mg/m2/day. At this dose level, fatigue and diarrhea of grade 1 or 2 were the most frequent toxicities and no significant hematologic toxicity was observed. Two complete and 3 partial remissions were observed. Four of the responders had received a platinum agent and/or 5-FU in the past. There were no effects of DNA adduct levels on toxicity or response. Conclusions: A sequential treatment with capecitabine, cisplatin and irinotecan is well tolerated and demonstrates clinical activity in patients with advanced solid malignancies. No significant financial relationships to disclose.
Characteristics and Risk for Progression of Smoldering Multiple Myeloma: Japanese Nationwide Retrospective Survey
Authors: Tsuyoshi Muta, Shinsuke Iida, Kosei Matsue, Kazutaka Sunami, Jun Isoda, Naoko Harada, Junya Kuroda, Toshihiro Miyamoto, Koichi Akashi, Yasushi Takamatsu
Journal: Annals of Oncology (2014)
Results of a Phase II Study Using Estramustine Phosphate and Vinblastine in Combination With High-Dose Three-Dimensional Conformal Radiotherapy for Patients With Locally Advanced Prostate Cancer
Authors: Michael J. Zelefsky, William K. Kelly, Howard I. Scher, Henry Lee, Tracy Smart, Erica Metz, Lawrence Schwartz, Zvi Fuks, Steven A. Leibel
Journal: Journal of Clinical Oncology (2000)

PURPOSE: To assess the feasibility and tolerance of neoadjuvant and concomitant estramustine phosphate and vinblastine (EV) with high-dose three-dimensional conformal radiotherapy (3D-CRT) for patients with unfavorable-risk prostate cancer. PATIENTS AND METHODS: Twenty-seven patients with unfavorable-risk prostate cancer were enrolled onto a prospective study to determine the feasibility of combining EV with 3D-CRT. Patients were eligible if any of the following requirements were satisfied: (1) Gleason score ≥ 8 and prostate-specific antigen (PSA) &gt; 10 ng/mL; (2) Gleason score of 7 and PSA &gt; 20 ng/mL; (3) clinical stage T3N0M0 disease with PSA &gt; 20 ng/mL; (4) any patient with T4N0M0 disease; or (5) patients with TXN1MO disease. Therapy consisted of three 8-week cycles of EV and 8 weeks of 3D-CRT. Estramustine phosphate was given orally beginning on week 1 and continued until the completion of 3D-CRT. Each 8-week cycle of vinblastine consisted of 6 weekly intravenous injections followed by a 2-week rest period. Radiation therapy was administered using a three-dimensional conformal approach to a prescription dose of 75.6 Gy. The median follow-up was 26 months (range, 6 to 40 months). RESULTS: Twenty-three (85%) of 27 patients completed the entire course of therapy and were assessable for toxicities and biochemical outcome. Two patients (7%) developed grade 3 hematologic toxicity that resolved, and two patients (7%) developed grade 3 hepatoxicity, manifesting as persistent elevation of serum transaminase levels, necessitating discontinuation of the chemotherapy and withdrawal from the treatment program. The most prominent adverse effects from this regimen were mild to moderate (grade 1 to 2) nausea and fatigue related to estramustine. Mild peripheral edema was seen in 15% of patients and was treated with diuresis. 3D-CRT was tolerated well in these patients. Medications were required for relief of acute grade 2 rectal (gastrointestinal [GI]) and urinary (genitourinary [GU]) symptoms in 35% and 48% of patients, respectively. Three patients developed acute grade 3 GU toxicities. The 2-year actuarial likelihood of late grade 2 GI toxicity was 20%. No late grade 3 or 4 GI toxicities were observed. The 2-year actuarial likelihoods of late grade 2 and 3 GU toxicities were 25% and 12%, respectively. No grade 4 GU toxicity was observed. CONCLUSION: Neoadjuvant and concomitant EV with high-dose 3D-CRT is well tolerated in patients with unfavorable-risk prostate cancer. Although the incidence of modest (grade 2) late GI and GU toxicities seem to be increased compared with 3D-CRT alone or in combination with androgen ablation therapy, no severe toxicities were encountered with this regimen.
Circulating biomarker tissue kallikrein-related peptidase KLK5 impacts ovarian cancer patients’ survival
Authors: J. Dorn, V. Magdolen, A. Gkazepis, T. Gerte, A. Harlozinska, P. Sedlaczek, E.P. Diamandis, T. Schuster, N. Harbeck, M. Kiechle, M. Schmitt
Journal: Annals of Oncology (2011)